MIRA
MIRA PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$0.57
+1.87%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -63.7%
- EBIT
- -19.4%
- EPS
- —
- Free cash flow
- +23.7%
- Operating cash flow
- +23.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +89.1%
Three-year CAGR
- Revenue
- —
- EBITDA
- -30.2%
- EBIT
- -30.9%
- Net income
- -33.0%
- EPS
- —
- Free cash flow
- +16.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026